Egf/egfr complex interaction studies by surface plasmon resonance

Authors

  • Johana Hysomema

DOI:

https://doi.org/10.55312/op.vi2.4366

Abstract

Epidermial growth factor receptor (EGFR) abnormalities are associated with all aspects of carcinogenesis: cell proliferation, inhibition of apoptosis, angiogenesis and metastasis. Overexpression of EGFR has been reported in several tumor types, most notably colorectal, head and neck, and lung cancers, where it typically correlates with poor clinical outcomes. Thus, interference with EGFR receptor activation, owing to the binding of ligands such as epidermal growth factor (EGF), and/or with its intracellular signal transduction pathways represents a promising strategy for the development of novel and selective anticancer therapies. This work was focused on surface plasmon resonance (SPR) investigation of the direct EGF/EGFR complex interaction using three diff erent experimental approaches.

Keywords:

EGF, EGFR, interaction, surface plasmon resonance.

Downloads

Download data is not yet available.

Author Biography

Johana Hysomema

Departamenti i Infermierisë dhe Fizioterapisë, Albanian University, Shqipëri

References

  1. . Yoshimoto, Y. and Imoto, M. Induction of EGF-dependent apoptosis by vacuolar-type H+- ATPase inhibitors in A431 cells overexpressing

  2. the EGF receptor. Experimental Cell Research 2002; 279; 118–27.

  3. . Zhou, M., Felder, S., Rubinstein, M., Hurwitz, D.R., Ullrich, A., Lax, I., Schlessinger, J. Real- Time measurements of kinetics of EGF binding

  4. to soluble EGF receptor monomers and dimers support the dimerization model for receptor activation. Biochemistry 1993; 32; 8193-8.

  5. . Yarden, Y. and Sliwkowski, M.X. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001; 2; 127-37.

  6. . Hanahan, D., Weinberg, R.A. The hallmarks of cancer. Cell 2000; 100; 57–70.

  7. . Yarden, Y., The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;

  8. Suppl 4; S3–8.

  9. . Nyati, M.K., Morgan, M.A., Feng, F.Y., Lawrence, T.S. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006;

  10. . Meyerhardt, J.A., Kwok, A., Ratain, M.J., McGovren, J.P., Fuchs, C.S. Relationship of baseline serum bilirubin to effi cacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2004; 22; 1439–46.

  11. . Mackenzie, M.J., Hirte, H.W., Glenwood, G., et al. A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor

  12. receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs 2005; 23; 165-70.

  13. . Townsley, C.A., Major, P., Siu, L.L., et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer; 2006; 94; 1136-43.

  14. . Bardelli, A., Siena, S. Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer. J Clin Oncol 2010; 28;

  15. -61.

  16. . Shankaran, V., Obel, J., Benson, A.B. 3rd. Predicting Response to EGFR Inhibitors in Metastatic Colorectal Cancer: Current Practice

  17. and Future Directions. Oncologist 2010; 15; 157-67.

  18. . Capdevila, J., Elez, E., Macarulla, T., et al. Antiepidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat

  19. Rev 2009; 3 5; 354–63.

  20. . Liedberg, B., Nylander, C., Lundstrom, I. Surface plasmon resonance for gas detection and biosensing. Sensors Actuators 1983; 4; 299-304.

  21. . Fägerstam, L.G., Frostell-Karlsson, A., Karlsson, R., Persson, B., Rönnberg, I. Biospecifi c interaction analysis using surface plasmon resonance detection applied to kinetic, binding site and concentration analysis. J Chromatogr 1992; 597; 397–410.

  22. . Myszka, D.G., Jonsen, M.D., Graves, B.J. Equilibrium analysis of high affi nity interactions using BIACORE. Anal Biochem 1998; 265; 326–30.

  23. . Wilson, W.D. Analyzing biomolecular interactions. Science 2002; 295; 2103–5.

  24. . Cooper, M.A. Optical biosensors in drug discovery. Nat Rev Drug Discov 2002; 1; 515–28.

  25. . Haigler, H., Ash, J. F., Singer, S. J., Cohen, S. Visualization by fl uorescence of the binding and internalization of epidermal growth factor

  26. in human carcinoma cells A-431. Proc Natl Acad Sci USA 1978; 75; 3317–21.

  27. . Yoshimoto, Y. and Imoto, M. Induction of EGFDependent Apoptosis by Vacuolar-Type H+- ATPase Inhibitors in A431 Cells Overexpressing

  28. the EGF Receptor. Experimental Cell Research 2002; 279; 118–27.

  29. . Varkondi, E., Schäfer, E., Bökönyi, G., et al. Comparison of ELISA-based tyrosine kinase assays for screening EGFR inhibitors. Journal of Receptors and Signal Transduction Res 2005; 25; 45-56.

  30. . Nice, E., Lackmann, M., Smyth, F., Fabri, L., Burgess, A.W. Synergies between micropreparative high-performance liquid chromatography and an instrumental optical biosensor. J Chromatogr A 1994; 660; 69-85.

  31. . Stenlund, P., Babcock, G., Sodroski, J., Myszka, D. Capture and Reconstitution of G-protein Receptors on a Biosensor Surface. Analytical Biochemistry 2003; 316; 243-50.

  32. Yarden, Y, Sliwkowski, M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2; 127–137.

Downloads

Published

2024-05-10

How to Cite

Hysomema, J. (2024). Egf/egfr complex interaction studies by surface plasmon resonance. Optime, (2), 73–82. https://doi.org/10.55312/op.vi2.4366

Issue

No. 2 (2015): Optime

Section

Articles

Categories